PH16794A - The(r'r)optical isomer of labetalol,its pharmaceutically acid addition salts and pharmaceutical composition containing them - Google Patents

The(r'r)optical isomer of labetalol,its pharmaceutically acid addition salts and pharmaceutical composition containing them

Info

Publication number
PH16794A
PH16794A PH23042A PH23042A PH16794A PH 16794 A PH16794 A PH 16794A PH 23042 A PH23042 A PH 23042A PH 23042 A PH23042 A PH 23042A PH 16794 A PH16794 A PH 16794A
Authority
PH
Philippines
Prior art keywords
acid addition
optical isomer
labetalol
addition salts
pharmaceutical composition
Prior art date
Application number
PH23042A
Other languages
English (en)
Inventor
Elijah H Gold
Wei Chang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PH16794A publication Critical patent/PH16794A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epoxy Compounds (AREA)
PH23042A 1978-09-20 1979-09-17 The(r'r)optical isomer of labetalol,its pharmaceutically acid addition salts and pharmaceutical composition containing them PH16794A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94451678A 1978-09-20 1978-09-20

Publications (1)

Publication Number Publication Date
PH16794A true PH16794A (en) 1984-02-28

Family

ID=25481553

Family Applications (1)

Application Number Title Priority Date Filing Date
PH23042A PH16794A (en) 1978-09-20 1979-09-17 The(r'r)optical isomer of labetalol,its pharmaceutically acid addition salts and pharmaceutical composition containing them

Country Status (27)

Country Link
EP (1) EP0009702B1 (el)
JP (3) JPS5555147A (el)
KR (2) KR830000904A (el)
AT (1) ATE351T1 (el)
AU (1) AU528626B2 (el)
CA (1) CA1151211A (el)
CY (1) CY1175A (el)
DD (1) DD150457A5 (el)
DE (1) DE2961263D1 (el)
DK (1) DK387579A (el)
FI (1) FI792884A (el)
GR (1) GR73179B (el)
HK (1) HK13383A (el)
HU (1) HU185523B (el)
IE (1) IE49301B1 (el)
IL (1) IL58258A (el)
KE (1) KE3283A (el)
MY (1) MY8500042A (el)
NO (1) NO149660C (el)
NZ (1) NZ191589A (el)
OA (1) OA06339A (el)
PH (1) PH16794A (el)
PL (1) PL129114B1 (el)
PT (1) PT70191A (el)
SG (1) SG283G (el)
YU (1) YU227379A (el)
ZA (1) ZA794872B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658060A (en) * 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
IT1194406B (it) * 1983-09-27 1988-09-22 Scharper S P A Procedimento per la preparazione di 2-idrossi-5-01-idrossi-2-((4-fenil-2-butil)ammino) etil benzammide
HU190867B (en) * 1984-01-20 1986-11-28 Egyt Gyogyszervegyeszeti Gyar,Hu Process for preparing 2-hydroxy-5-/1-hydroxy-2-/1-methyl-3-phenyl-propyl/-amino/ethyl/-benzamide and pharmaceutically acceptable salts thereof
US4788183A (en) * 1987-11-30 1988-11-29 Schering Corporation Method for treatment of dyslipidemia in humans
US4879233A (en) * 1989-02-10 1989-11-07 Schering Corporation Novel Aspergillus niveus microorganism used for the chiral reduction of carbonyl groups
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
JP2728564B2 (ja) * 1991-08-23 1998-03-18 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド カルシウム受容体活性化分子
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CZ290670B6 (cs) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
PT907631E (pt) * 1996-05-01 2003-10-31 Nps Pharma Inc Compostos inorganicos activos como receptores de ioes
IT1313583B1 (it) * 1999-07-30 2002-09-09 Chiesi Farma Spa Derivati 2-amminotetralinici per la terapia del glaucoma.
SI1961735T1 (sl) * 2007-02-22 2010-01-29 Indena Spa Postopek za pripravo acetatne soli (2r,3s)-3-fenilizoserin-metilestra
EP2603215A4 (en) 2010-08-11 2015-08-05 Philadelphia Health & Educatio NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1266058A (el) * 1969-07-08 1972-03-08
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
GB1541933A (en) * 1975-04-17 1979-03-14 Scherico Ltd Pharmaceutical compositions containing a diastereoisomer of a phenylalkylaminoethanol derivative

Also Published As

Publication number Publication date
IE791770L (en) 1980-03-20
DE2961263D1 (en) 1982-01-14
DD150457A5 (de) 1981-09-02
MY8500042A (en) 1985-12-31
IL58258A0 (en) 1979-12-30
ZA794872B (en) 1980-11-26
YU227379A (en) 1983-06-30
DK387579A (da) 1980-03-21
NO792993L (no) 1980-03-21
IE49301B1 (en) 1985-09-18
KE3283A (en) 1983-05-13
NO149660C (no) 1984-05-30
EP0009702B1 (en) 1981-11-04
NZ191589A (en) 1984-03-30
FI792884A (fi) 1980-03-21
ATE351T1 (de) 1981-11-15
AU528626B2 (en) 1983-05-05
KR840005307A (ko) 1984-11-05
CY1175A (en) 1983-06-10
PL129114B1 (en) 1984-03-31
HU185523B (en) 1985-02-28
OA06339A (fr) 1981-06-30
NO149660B (no) 1984-02-20
CA1151211A (en) 1983-08-02
EP0009702A1 (en) 1980-04-16
JPH02167253A (ja) 1990-06-27
JPH0210128B2 (el) 1990-03-06
IL58258A (en) 1984-01-31
JPS59108749A (ja) 1984-06-23
AU5088179A (en) 1980-03-27
HK13383A (en) 1983-04-29
KR890001998B1 (ko) 1989-06-07
PL218408A1 (el) 1980-09-08
PT70191A (en) 1979-10-01
SG283G (en) 1983-09-16
KR830000904A (ko) 1983-04-28
GR73179B (el) 1984-02-14
JPS5555147A (en) 1980-04-22

Similar Documents

Publication Publication Date Title
PH16794A (en) The(r'r)optical isomer of labetalol,its pharmaceutically acid addition salts and pharmaceutical composition containing them
AU683442B2 (en) Aminoacid derivates, medicaments containing these compounds and process for preparing the same
CA2168023A1 (en) Vasoconstrictive substituted aryloxyalkyl diamines
ES8506729A1 (es) Un procedimiento para preparar nuevos compuestos de cefem
AU624031B2 (en) Compositions and their use in lowering intraocular pressure
PT90022A (pt) Processo para a preparacao de derivados cefem e dos intermediarios correspondentes
ATE48001T1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate.
DK562488A (da) Farmaceutisk praeparat indeholdende polyminderivater, samt nogle af disse polyaminderivater
PL326554A1 (en) Derivatives of amine and thiourea and inhibitors of nitrogen oxide synthase
WO1990003172A3 (en) Bile acids for treatment of viral infections
ES524375A0 (es) Un procedimiento para preparar un compuesto de nitrato piridilalquilico
IL69448A (en) Process for combating phytopathogenic fungi with azolylphenoxy-tetrahydrofuran-2-ylidene methane derivatives
ES8400397A1 (es) Un procedimiento para la preparacion de un nuevo peptido activo.
ES8305307A1 (es) Un procedimiento para la preparacion de un aciltripeptido.
JPS5540601A (en) New 3-(3,4-dihydroxyphenyl)serine derivative
JPS54145615A (en) Derivative of (1,3)-beta-d-glucane, its use and preparation